Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

MedXY Editorial Team•Nov 17, 2025•Clinical Updates

The large, randomized STAMPEDE platform trial found no significant overall survival benefit with adding metformin to standard ADT-based therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
Metformin consistently demonstrated mitigation of adverse metabolic effects associated with ADT, including reductions in body weight, waist circumference, and glycemic markers in various trials.
Early-phase and smaller trials suggest possible improvements in progression parameters like castration-resistant prostate cancer-free survival (CRPC-FS), particularly in low-volume metastatic disease, but these findings require further validation.
Metformin’s safety profile in prostate cancer patients undergoing ADT is favorable with expected gastrointestinal adverse events, mainly diarrhea; no significant increase in severe toxicities was observed.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The large, randomized STAMPEDE platform trial found no significant overall survival benefit with adding metformin to standard ADT-based therapy in metastatic hormone-sensitive prostate cancer (mHSPC).
Metformin consistently demonstrated mitigation of adverse metabolic effects associated with ADT, including reductions in body weight, waist circumference, and glycemic markers in various trials.
Early-phase and smaller trials suggest possible improvements in progression parameters like castration-resistant prostate cancer-free survival (CRPC-FS), particularly in low-volume metastatic disease, but these findings require further validation.
Metformin’s safety profile in prostate cancer patients undergoing ADT is favorable with expected gastrointestinal adverse events, mainly diarrhea; no significant increase in severe toxicities was observed.